0 CHECKOUT

Hemophilia A - Pipeline Review, H1 2015

  • ID: 3334689
  • June 2015
  • 166 pages
  • Global Markets Direct
1 of 4

FEATURED COMPANIES

  • Amarna Therapeutics B.V.
  • Bayer AG
  • DBV Technologies S.A.
  • F. Hoffmann-La Roche Ltd.
  • Novo Nordisk A/S
  • Pharming Group N.V.
  • MORE

Hemophilia A - Pipeline Review, H1 2015

Summary

This, ‘Hemophilia A - Pipeline Review, H1 2015’, provides an overview of the Hemophilia A’s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Hemophilia A, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Hemophilia A and special features on late-stage and discontinued projects.

This report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from This proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by This team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes READ MORE >

Note: Product cover images may vary from those shown
2 of 4

FEATURED COMPANIES

  • Amarna Therapeutics B.V.
  • Bayer AG
  • DBV Technologies S.A.
  • F. Hoffmann-La Roche Ltd.
  • Novo Nordisk A/S
  • Pharming Group N.V.
  • MORE

List of Tables
List of Figures
Introduction
REPORT COVERAGE
Hemophilia A Overview
Therapeutics Development
Pipeline Products for Hemophilia A - Overview
Pipeline Products for Hemophilia A - Comparative Analysis
Hemophilia A - Therapeutics under Development by Companies
Hemophilia A - Therapeutics under Investigation by Universities/Institutes
Hemophilia A - Pipeline Products Glance
Late Stage Products
Clinical Stage Products
Early Stage Products
Unknown Stage Products
Hemophilia A - Products under Development by Companies
Hemophilia A - Products under Investigation by Universities/Institutes
Hemophilia A - Companies Involved in Therapeutics Development
Alnylam Pharmaceuticals, Inc.
Amarna Therapeutics B.V.
Apitope International NV
AstraZeneca Plc
Bayer AG
Biogen, Inc.
BioMarin Pharmaceutical Inc.
Catalyst Biosciences, Inc.
Celtic Pharmaceutical Holdings L.P.
CSL Limited
DBV Technologies S.A.
Dimension Therapeutics, Inc.
Dong-A Socio Group
Emergent BioSolutions Inc.
EpiVax, Inc.
Expression Therapeutics LLC
F. Hoffmann-La Roche Ltd.
Green Cross Corporation
Inbiopro Solutions Pvt. Ltd.
Lentigen Technology, Inc.
Novo Nordisk A/S
Octapharma AG
OPKO Health, Inc.
Pharming Group N.V.
Promethera Biosciences S.A.
rEVO Biologics
Sangamo BioSciences, Inc.
Selecta Biosciences, Inc.
SK Chemicals Co., Ltd.
Spark Therapeutics, Inc.
The International Biotechnology Center (IBC) “Generium”
uniQure N.V.
Hemophilia A - Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
ALN-AT3 - Drug Profile
antihemophilic factor (recombinant) - Drug Profile
antihemophilic factor (recombinant) - Drug Profile
antihemophilic factor (recombinant) - Drug Profile
antihemophilic factor (recombinant) - Drug Profile
antihemophilic factor (recombinant) - Drug Profile
antihemophilic factor (recombinant) - Drug Profile
antihemophilic factor (recombinant), fc fusion protein - Drug Profile
ATXF-8117 - Drug Profile
AZ-10047130 - Drug Profile
BAX-826 - Drug Profile
BAX-855 - Drug Profile
BAX-888 - Drug Profile
BAY-1093884 - Drug Profile
BAY-818973 - Drug Profile
BMN-270 - Drug Profile
coagulation factor VIIa (recombinant) - Drug Profile
concizumab - Drug Profile
CSL-689 - Drug Profile
DA-3808 - Drug Profile
damoctocog alfa pegol - Drug Profile
Deimmunized FVIII - Drug Profile
DTX-201 - Drug Profile
eptacog alfa biosimilar - Drug Profile
ET-3 - Drug Profile
Gene Therapy for Bleeding and Clotting Disorders - Drug Profile
Gene Therapy for Hemophilia A - Drug Profile
Gene Therapy for Hemophilia A - Drug Profile
Gene Therapy for Hemophilia A - Drug Profile
GNR-002 - Drug Profile
HepaStem - Drug Profile
IBPH-001OC - Drug Profile
LG-889 - Drug Profile
LR-769 - Drug Profile
MOD-5014 - Drug Profile
PF-05280602 - Drug Profile
Protein for Hemophilia A - Drug Profile
Proteins for Hemophilia A - Drug Profile
Recombinant Protein for Hemophilia A - Drug Profile
Recombinant Protein to Replace Factor VIII for Hemophilia A - Drug Profile
Recombinant Protein to Replace Factor VIII for Hemophilia A - Drug Profile
RG-6013 - Drug Profile
SEL-201 - Drug Profile
SVF-VIIa - Drug Profile
turoctocog alfa pegol - Drug Profile
Hemophilia A - Recent Pipeline Updates
Hemophilia A - Dormant Projects
Hemophilia A - Discontinued Products
Hemophilia A - Product Development Milestones
Featured News & Press Releases
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables
Number of Products under Development for Hemophilia A, H1 2015
Number of Products under Development for Hemophilia A - Comparative Analysis, H1 2015
Number of Products under Development by Companies, H1 2015
Number of Products under Development by Companies, H1 2015 (Contd..1)
Number of Products under Development by Companies, H1 2015 (Contd..2)
Number of Products under Investigation by Universities/Institutes, H1 2015
Comparative Analysis by Late Stage Development, H1 2015
Comparative Analysis by Clinical Stage Development, H1 2015
Comparative Analysis by Early Stage Development, H1 2015
Comparative Analysis by Unknown Stage Development, H1 2015
Products under Development by Companies, H1 2015
Products under Development by Companies, H1 2015 (Contd..1)
Products under Development by Companies, H1 2015 (Contd..2)
Products under Development by Companies, H1 2015 (Contd..3)
Products under Investigation by Universities/Institutes, H1 2015
Hemophilia A - Pipeline by Alnylam Pharmaceuticals, Inc., H1 2015
Hemophilia A - Pipeline by Amarna Therapeutics B.V., H1 2015
Hemophilia A - Pipeline by Apitope International NV, H1 2015
Hemophilia A - Pipeline by AstraZeneca Plc, H1 2015
Hemophilia A - Pipeline by Bayer AG, H1 2015
Hemophilia A - Pipeline by Biogen, Inc., H1 2015
Hemophilia A - Pipeline by BioMarin Pharmaceutical Inc., H1 2015
Hemophilia A - Pipeline by Catalyst Biosciences, Inc., H1 2015
Hemophilia A - Pipeline by Celtic Pharmaceutical Holdings L.P., H1 2015
Hemophilia A - Pipeline by CSL Limited, H1 2015
Hemophilia A - Pipeline by DBV Technologies S.A., H1 2015
Hemophilia A - Pipeline by Dimension Therapeutics, Inc., H1 2015
Hemophilia A - Pipeline by Dong-A Socio Group, H1 2015
Hemophilia A - Pipeline by Emergent BioSolutions Inc., H1 2015
Hemophilia A - Pipeline by EpiVax, Inc., H1 2015
Hemophilia A - Pipeline by Expression Therapeutics LLC, H1 2015
Hemophilia A - Pipeline by F. Hoffmann-La Roche Ltd., H1 2015
Hemophilia A - Pipeline by Green Cross Corporation, H1 2015
Hemophilia A - Pipeline by Inbiopro Solutions Pvt. Ltd., H1 2015
Hemophilia A - Pipeline by Lentigen Technology, Inc., H1 2015
Hemophilia A - Pipeline by Novo Nordisk A/S, H1 2015
Hemophilia A - Pipeline by Octapharma AG, H1 2015
Hemophilia A - Pipeline by OPKO Health, Inc., H1 2015
Hemophilia A - Pipeline by Pharming Group N.V., H1 2015
Hemophilia A - Pipeline by Promethera Biosciences S.A., H1 2015
Hemophilia A - Pipeline by rEVO Biologics, H1 2015
Hemophilia A - Pipeline by Sangamo BioSciences, Inc., H1 2015
Hemophilia A - Pipeline by Selecta Biosciences, Inc., H1 2015
Hemophilia A - Pipeline by SK Chemicals Co., Ltd., H1 2015
Hemophilia A - Pipeline by Spark Therapeutics, Inc., H1 2015
Hemophilia A - Pipeline by The International Biotechnology Center (IBC) “Generium”, H1 2015
Hemophilia A - Pipeline by uniQure N.V., H1 2015
Assessment by Monotherapy Products, H1 2015
Number of Products by Stage and Target, H1 2015
Number of Products by Stage and Mechanism of Action, H1 2015
Number of Products by Stage and Route of Administration, H1 2015
Number of Products by Stage and Molecule Type, H1 2015
Hemophilia A Therapeutics - Recent Pipeline Updates, H1 2015
Hemophilia A - Dormant Projects, H1 2015
Hemophilia A - Dormant Projects (Contd..1), H1 2015
Hemophilia A - Discontinued Products, H1 2015

List of Figures
Number of Products under Development for Hemophilia A, H1 2015
Number of Products under Development for Hemophilia A - Comparative Analysis, H1 2015
Number of Products under Development by Companies, H1 2015
Comparative Analysis by Late Stage Development, H1 2015
Comparative Analysis by Clinical Stage Development, H1 2015
Comparative Analysis by Early Stage Products, H1 2015
Assessment by Monotherapy Products, H1 2015
Number of Products by Top 10 Targets, H1 2015
Number of Products by Stage and Top 10 Targets, H1 2015
Number of Products by Top 10 Mechanism of Actions, H1 2015
Number of Products by Stage and Top 10 Mechanism of Actions, H1 2015
Number of Products by Top 10 Routes of Administration, H1 2015
Number of Products by Stage and Top 10 Routes of Administration, H1 2015
Number of Products by Top 10 Molecule Types, H1 2015
Number of Products by Stage and Top 10 Molecule Types, H1 2015

Note: Product cover images may vary from those shown
3 of 4

Alnylam Pharmaceuticals, Inc.
Amarna Therapeutics B.V.
Apitope International NV
AstraZeneca Plc
Bayer AG
Biogen, Inc.
BioMarin Pharmaceutical Inc.
Catalyst Biosciences, Inc.
Celtic Pharmaceutical Holdings L.P.
CSL Limited
DBV Technologies S.A.
Dimension Therapeutics, Inc.
Dong-A Socio Group
Emergent BioSolutions Inc.
EpiVax, Inc.
Expression Therapeutics LLC
F. Hoffmann-La Roche Ltd.
Green Cross Corporation
Inbiopro Solutions Pvt. Ltd.
Lentigen Technology, Inc.
Novo Nordisk A/S
Octapharma AG
OPKO Health, Inc.
Pharming Group N.V.
Promethera Biosciences S.A.
rEVO Biologics
Sangamo BioSciences, Inc.
Selecta Biosciences, Inc.
SK Chemicals Co., Ltd.
Spark Therapeutics, Inc.
The International Biotechnology Center (IBC) “Generium”
uniQure N.V.

Note: Product cover images may vary from those shown
4 of 4
Note: Product cover images may vary from those shown

PLEASE SELECT A FORMAT

  • Quick Help: The report will be emailed to you. The report is sent in PDF format. This is a single user license, allowing one specific user access to the product.

  • Quick Help: The report will be emailed to you. The report is sent in PDF format. This is a site license, allowing all users within a given geographical location of your organisation access to the product.

  • Quick Help: The report will be emailed to you. The report is sent in PDF format. This is an enterprise license, allowing all employees within your organisation access to the product.

HAVE A QUESTION?

If you have a more general question about our products please try our

FAQ SECTION

RELATED PRODUCTS from Db

Our Clients

  • Amneal Pharmaceuticals LLC.
  • Amgen Inc.
  • LEO Laboratories Ltd.
  • Pfizer Inc.
  • Roche Diagnostics Ltd.
  • Merck & Co., Inc.
  • Sanofi S.A.